Literature DB >> 28839820

Statin therapy in patients with cirrhosis.

Andrew P Wright1,2, Srinath Adusumalli1,2, Kathleen E Corey2,3.   

Abstract

Cardiovascular disease is one of the leading causes of death among patients with cirrhosis and following liver transplantation. Although 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors ('statins') reduce the risk of cardiovascular events, fears about hepatotoxicity have historically led to underuse in patients with liver disease. In addition, the pharmacokinetics of statins can be significantly altered in cirrhosis, creating challenges with their use in liver disease. However, emerging data from randomised controlled trials and observational studies suggest that statin therapy appears to be safe and effective in patients with chronic liver disease and compensated cirrhosis. The cardiovascular risk benefits as well as the potential pleiotropic benefits of statins warrants strong consideration of use of statin therapy in patients with cirrhosis.

Entities:  

Keywords:  CARDIOVASCULAR DISEASE; FATTY LIVER; LIPIDS

Year:  2014        PMID： 28839820      PMCID： PMC5369584          DOI： 10.1136/flgastro-2014-100500

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


  57 in total

Review 1.  Cellular and molecular basis of portal hypertension.

Authors:  V Shah
Journal:  Clin Liver Dis       Date:  2001-08       Impact factor: 6.126

2.  Yes! Statins can be given to liver patients.

Authors:  Ted Bader
Journal:  J Hepatol       Date:  2011-09-29       Impact factor: 25.083

3.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.

Authors:  Yu-Tse Tsan; Chang-Hsing Lee; Jung-Der Wang; Pau-Chung Chen
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

4.  Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Authors:  Stephen A Harrison; Lorenzo Rossaro; Ke-Qin Hu; Keyur Patel; Hans Tillmann; Sandeep Dhaliwal; Dawn M Torres; Kenneth Koury; Venkata S Goteti; Stephanie Noviello; Clifford A Brass; Janice K Albrecht; John G McHutchison; Mark S Sulkowski
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark.

Authors:  Henrik Toft Sørensen; Ane Marie Thulstrup; Lene Mellemkjar; Peter Jepsen; Erik Christensen; Jørgen H Olsen; Hendrik Vilstrup
Journal:  J Clin Epidemiol       Date:  2003-01       Impact factor: 6.437

6.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

7.  Ten years of liver transplantation: an evolving understanding of late graft loss.

Authors:  O Abbasoglu; M F Levy; B B Brkic; G Testa; D R Jeyarajah; R M Goldstein; B S Husberg; T A Gonwa; G B Klintmalm
Journal:  Transplantation       Date:  1997-12-27       Impact factor: 4.939

8.  Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies.

Authors:  Abdurrahman Kadayifci; Vivian Tan; Philip C Ursell; Raphael B Merriman; Nathan M Bass
Journal:  J Hepatol       Date:  2008-06-27       Impact factor: 25.083

9.  Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.

Authors:  Jonel Trebicka; Martin Hennenberg; Wim Laleman; Nataliya Shelest; Erwin Biecker; Michael Schepke; Frederik Nevens; Tilman Sauerbruch; Jörg Heller
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

10.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.

Authors:  Q Zhou; M Hennenberg; J Trebicka; K Jochem; L Leifeld; E Biecker; T Sauerbruch; J Heller
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059
View more
  3 in total

Review 1.  Use of Statins in Patients With and Without Liver Disease.

Authors:  Prashanth Francis; Lisa Forman
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-02-25

2.  A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.

Authors:  Shuen Sung; Mustafa Al-Karaghouli; Sylvia Kalainy; Lourdes Cabrera Garcia; Juan G Abraldes
Journal:  BMC Gastroenterol       Date:  2021-03-16       Impact factor: 3.067

3.  Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.

Authors:  Yue Gu; Xueqin Yang; Hang Liang; Deli Li
Journal:  BMC Gastroenterol       Date:  2019-12-30       Impact factor: 3.067
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.